How we pick leaders — in 30 seconds
We rank market themes by relative strength, find the strongest names inside the leading themes, and verify every quote and return against live market data at publish time. Each name gets one call: Buyable (at a buy point) · Basing (watch for a breakout) · Wait (strong, no setup yet) · Extended (overbought, await a pullback) · Too early (unconfirmed bounce) · Avoid (downtrend). Relative strength is a descriptive, backward-looking signal — not a forecast.
Market regime
As of the 2026-06-03 close, semiconductors lead every trailing window. SMH is up 77% year-to-date, sitting at a fresh 52-week high and 63% above its 200-day.
Today's red mega-cap tape (NVDA -3.55%, SMCI -5.48%) is one-day profit-taking inside an intact, parabolic uptrend, not a trend break. Leadership is visibly migrating beneath the GPU layer into memory/HBM, custom silicon, and the physical buildout that powers and cools data centers.
The cleanest live tell: Micron held GREEN at its 52-week high on a hard risk-off day, while NVDA, PLTR and AMZN sold off. That is leadership rotating into the memory bottleneck.
Two narrative errors got corrected by measured price. First, Healthcare is NOT defensive leadership: XLV is below its 200-day and 8% off its high, one of the worst major themes.
The leadership there is one name, Eli Lilly, not the sector. Second, breadth-broadening is weak: equal-weight RSP (+9.2% YTD) slightly lags cap-weight SPY (+10.6%), so the index is not being secretly carried by the average stock.
Energy is a genuine YTD leader (XLE +31%) but decelerating and stalled on its 50-day. Beneath the surface a clean risk-off split is active: durable AI-infra (memory, ASICs, power, cooling, cybersecurity) and large-cap pharma held green, while the speculative complex (quantum, SMR/uranium-spec, crypto/stablecoin equities) sold off 7-12%.
Net read: trend intact and extended. Chase strength down the AI stack and into genuinely-early laggard recoveries like biotech.
Respect that the leaders sit at asymmetric reward/risk, and do not mistake a one-day defensive print for a regime change. Note: not every theme was independently re-verified at the single-name level — see caveats.
Energy is a genuine YTD leader (XLE +31%) but decelerating and stalled on its 50-day.
Theme strength & rotation
Each theme’s leadership strength (0–100, from its leaders’ proximity to 52-wk highs, relative strength vs the proxy, and momentum), tracked across issues. ▲ strengthening · ▼ rolling over · ● holding · ✦ new. The number is the change vs the last issue this theme appeared. A theme that is rising but not yet at the top is where leadership may be emerging.
Leadership map
AI Semiconductors / Compute
AI memory / HBM super-cycle
What’s driving it. A genuine DRAM/HBM shortage. Micron is verified at $1,079.57, up 1.45% and GREEN at its 52-week high ($1,088.89), trading ~3.1x its 200-day ($348).
Holding green while NVDA, PLTR and AMZN sold off is the tell that leadership is rotating into the memory bottleneck (MU +141% YTD, SanDisk +156% per web).
Durability. Short-to-medium term. Memory is historically boom-bust cyclical.
The 140-300% moves carry late-cycle risk if DRAM pricing rolls over. This is the highest-conviction CURRENT-momentum theme, but it is established-leading, not emerging — the easy money is behind it.
Leaders’ fundamental health. Improving sharply but cyclical. Micron's revenue is inflecting hard on pricing, margins are expanding off the trough.
Balance sheets are adequate. The whole group is geared to one variable — DRAM spot pricing — so fundamental health is only as durable as the shortage.
Data-center physical buildout — cooling & electricals
What’s driving it. Every AI data center needs power distribution and liquid cooling. Vertiv is verified at $331.44, only -0.91% on a hard tape, roughly 209% above its year low, with a 200-day of $213.
It is consolidating 13% below its high — digesting a run, not breaking. Morgan Stanley names it a core AI-infra leg.
Durability. Sustainable. This is the physical bottleneck of the AI buildout, with multi-year order backlogs.
It held green-ish (-0.9%) while spec-growth fell 6-12% on the same day, confirming it trades as durable infrastructure, not as a momentum chase.
Leaders’ fundamental health. Solid. These are profitable industrials (VRT, ETN, PWR) with real revenue growth, expanding margins, and order backlogs.
Valuations have run up with the trend, so the multiple is the watch-item, not the business.
Power-for-AI generation / IPPs
What’s driving it. AI data centers need enormous baseload power. GE Vernova is verified at $959.36 (-1.06%), up 46.8% YTD, with its gas-turbine backlog growing 83→100 GW in Q1 2026 plus $2.4B of data-center electrification orders.
Talen's 1,920 MW Amazon/AWS nuclear PPA (~$1.4B/yr through 2042) is the contracted-cash-flow anchor.
Durability. Sustainable for the equipment layer, more fragile for the merchant IPPs. GEV is consolidating below its 50-day ($1,004.81) but well above a rising 200-day ($751.63) — classic digestion.
The cash-flowing names held (GEV/CEG -1% to -2%) while speculative SMR names cratered 11-12%. The split is the signal: own the cash, avoid the story.
Leaders’ fundamental health. Bifurcated. GEV is genuinely healthy — net cash, ROE 44%, positive FCF, +9% revenue — but Stretched on valuation (EV/EBITDA ~46x).
Talen is the caution: FY2025 was a -$219M GAAP net loss with net-debt/EBITDA ~14.6x; its thesis rests entirely on contracted AWS cash flows, not current earnings. Verification downgraded TLN's health from the proposed Strong to Weak.
Copper — AI/electrification structural leader
What’s driving it. Copper is the metal of electrification and AI grid buildout. Copper hit a record ~$13,238/ton in early 2026 (web).
FCX is verified at $70.67, up 39.2% YTD and within 2% of its 52-week high, beating the COPX proxy on every horizon. TECK leads on 3-month and YTD price strength (+40.4% YTD).
Durability. Sustainable as a structural supply-deficit story, but individual names diverge sharply. Distinguish copper (above both MAs, durable) from gold/silver (rolled below the 50-day, late).
FCX is now extended (within 2% of its high after a +27% month) — basing names like SCCO are the cleaner entries.
Leaders’ fundamental health. Mixed across the group. SCCO has the best assets (60% EBITDA margin, 39% ROE, 0.39x net leverage) but is Stretched at ~15x EV/EBITDA.
FCX is Mixed — solid balance sheet, but thin FCF (~1.5% yield) and 33x P/E. TECK is the price leader but fundamentally WEAKEST: free cash flow is NEGATIVE, ROIC under 3%, capex ~2x operating cash flow.
The strong TECK tape is re-rating, not cash generation.
Cybersecurity
What’s driving it. AI-driven security spend and a relentless breach cycle. All three verified names crush the CIBR proxy: CRWD +90.8% over 3 months vs +43.3%, PANW +79.6%, FTNT +84.5% YTD.
CrowdStrike's Q1 FY27 print (today) was strong — record net-new ARR $256M +32% YoY, plus a 4-for-1 split.
Durability. Sustainable. Security is non-discretionary enterprise spend with high recurring revenue.
CRWD dipped only 2.78% on a hard tape while spec peers (COIN -6.2%, PLTR -6.5%) fell harder, confirming it trades as durable software. The risk is valuation, not demand.
Leaders’ fundamental health. A genuine quality spread. FTNT is the standout — cleanly GAAP-profitable, ROIC ~29%, ~$2.2B FCF, cheapest at ~8.5x EV/S — but the most extended (within 1.7% of its high).
PANW is GAAP-profitable with ~$3.5B FCF and a more digestible ~12x EV/S, carrying CyberArk integration overhang. CRWD is the richest (EV/S ~22x, EV/FCF ~80x) and still GAAP-loss-making with ~23% stock comp.
GLP-1 / obesity & large-cap pharma
What’s driving it. The obesity/GLP-1 super-cycle. Lilly is verified at $1,083.23, up 1.79% and GREEN, up 7.9% over 3 months while XLV fell 5.9%.
The FDA approved its oral GLP-1 Foundayo (orforglipron) on 2026-04-01 — the only any-time oral GLP-1, ~12.4% weight loss at 72 weeks — with a Q2-2026 launch. West Pharmaceutical is the verified pick-and-shovel leader (+25.8% over 3 months).
Durability. Sustainable at the franchise level, but this is a NARROW single-name story, not broad sector leadership. The Healthcare SECTOR is broken (XLV below its 200-day, -8% off its high).
Own LLY and WST as the true leadership pocket; the broad defensive-rotation thesis is wrong.
Leaders’ fundamental health. Best-in-class growth, stretched valuation. LLY is elite — revenue +44.7%, ROE 78%, ROIC 30% — but FCF yield is under 1% and EV/S ~15x, leaving no margin for error.
WST has a pristine net-cash balance sheet but trades at 40x P/E on mid-single-digit total revenue growth. ABBV is the laggard of the three (-7.2% over 3 months, below its 200-day), included only as a diversified-pharma challenger; its obesity exposure is pre-Phase-2 optionality.
Biotech laggard-to-leader (small/mid-cap)
What’s driving it. Falling rates improving small-cap funding, a ~$29B March-2026 biopharma M&A wave (patent-cliff driven), and a run of FDA gene-editing approvals. XBI is verified at $129.83 (+1.62%), bouncing off its 200-day ($118.33) while still BELOW its 50-day ($131.43) and ~7% under its 52-week high ($139.19) — the textbook recovering-laggard profile.
Durability. Potentially sustainable if the rate-cut and M&A cycle persists, but this is early and unconfirmed. The thesis rests on XBI's base-recovery structure, NOT on the day's single-name pops (ABVX +24.3% is idiosyncratic).
The cleanest reward/risk in the set because it has not yet extended.
Leaders’ fundamental health. Highly variable by name — this is an equal-weight, breadth theme. Anchors like VRTX and ALNY are profitable, cash-generative franchises; the small-cap tail (CRSP, MRNA, ABVX) is pre-profit and cash-burning.
Health here is a portfolio statement, not a single-name one; the basket (XBI) is the cleaner expression than picking names.
Selective medtech / device breakouts
What’s driving it. Stock-specific structural growth catalysts. Edwards is just below its 52-week high after a clean six-month base breakout, with Q1-2026 heart-therapy growth ~+42% YoY and raised FY guidance.
Glaukos is reclaiming its 200-day from below. The selectivity is the signal: ISRG is explicitly excluded as a falling knife at its 52-week low.
Durability. Short-term and fragile because it rests on 2-3 names. The broad device proxy IHI is the single weakest in the RS set (-25% off its high), so there is no sector tailwind underneath.
This is a stock-picker's theme, not a own-the-group theme.
Leaders’ fundamental health. The named breakouts (EW, BSX) are healthy — profitable, growing, reasonable balance sheets — but the proxy weakness signals the average device name is struggling. Lowest conviction in the set for exactly this reason: the health is concentrated in a handful of names, not the group.
Energy / oil & gas
What’s driving it. Cumulative 2026 strength on value-rotation, dividends and buybacks. XLE is +31% YTD but only +2.9% over 3 months and -1.2% over 1 month, sitting right ON its 50-day.
Verification confirmed 3 of 4 names lead (FANG +38% YTD, SLB +41%, EOG +32%) but WMB is an outright laggard — negative on both 1-month and 3-month while the proxy rose.
Durability. Tired, not fresh. The primary uptrend (above the 200-day) is intact, so this is extended-late rather than fading.
But crude fundamentals are bearish (WTI ~$59 2026 base case on non-OPEC supply per web), so equity strength is dividend/buyback-driven and could decouple from oil. Own the cheap, low-leverage names; avoid the stretched ones.
Leaders’ fundamental health. A wide spread. EOG is the quality leader — 11x earnings, net-debt/EBITDA 0.44x, 36x interest coverage, FCF yield ~7% — genuinely Strong.
SLB and FANG are Mixed: real FCF (FANG's $6.8B FCFE post-Endeavor) but YoY EPS declines on softer prices, and FANG absorbed a $3.7B impairment. WMB is Stretched and broken — net-debt/EBITDA ~3.95x, FCF yield 1.4%, P/E 28x, below its 50-day.
Verification reclassified WMB from leader to lagging.
Gold & precious metals
What’s driving it. Firmer labor data pushed back rate-cut odds, taking the wind out of the metal. GLD is below its 50-day ($425) and only marginally above its 200-day; GDX is below both MAs and -27.5% off its high — the deepest drawdown in the RS set.
Silver is more stretched still (SLV ~40% off its high).
Durability. Late-cycle digestion. The metals reflation is narrow and has shifted into copper and oil, NOT a broad bid.
Gold has moved from leadership to correction. This is a wait-for-a-base situation, not a buy.
Leaders’ fundamental health. Healthy underlying businesses (NEM, AEM, royalty names FNV/WPM are high-margin and cash-generative), but the price trend has broken down. Good companies in a correcting trend — the issue is the tape, not the fundamentals.
Quantum Computing
What’s driving it. The Quantinuum IPO (real and dated: $14.3B valuation, $53-55/share, >20x oversubscribed) is siphoning the institutional quantum dollar. RGTI is verified at $24.10 (-10.36%), -59% off its high, sitting ON its 200-day.
The whole complex sold off into the IPO. Importantly, the proxy ETF QTUM is itself near all-time highs — only the pure-plays are well below theirs.
Durability. Fading on momentum. Fundamentals are improving (IONQ revenue +755% YoY) but price leads them lower — a classic extended-theme unwind.
Verification found the biggest thesis error here: QBTS's growth story is false — recognized revenue is FALLING quarter over quarter ($15.0M → $2.86M, the lowest of five quarters), not compounding. The 'growth' is bookings optics.
Leaders’ fundamental health. IBM is the ONLY healthy name — P/E 26x, 16% net margin, 32% ROE, $14.4B FCF — but its quantum exposure is tiny, so it lagged the theme (+3.2% YTD). The three pure-plays (IONQ, QBTS, RGTI) are all Weak: deeply FCF-negative, dilution-funded, extreme EV/sales.
RGTI has NEGATIVE gross margin and only ~$48M cash. IONQ's and RGTI's headline 'GAAP profits' are non-operating warrant gains, not earnings — both ran large operating losses.
Uranium & nuclear / SMR
What’s driving it. Utilities reverted from spot-driven buying to long-term contracts, ending the spec spike (web). On the tape day URA fell 5.67%, OKLO -11.24%, LEU -8.77%, SMR -12%; even blue-chip CCJ fell ~5%.
Policy tailwinds (DOE SMR funding) are real, so the thesis is not dead — but the stocks are de-rating.
Durability. Fading. The cash-flowing power trade lives in GEV/CEG (separate theme); THIS is the spec fuel-cycle, which broke.
Verification corrected the proposed write-up: BWXT is NOT a leader — it is below both MAs, -14.8% over the past month, broken-avoid. Only CCJ survives the live tape as an actual RS leader, and even it is richly valued.
Leaders’ fundamental health. Weak-to-stretched across the board. CCJ generates real cash and is net-cash but trades at an extreme P/E ~93x / EV/EBITDA ~62x.
UEC is loss-making with negative FCF and chronic dilution. OKLO is pre-revenue, pre-licensing, burning -$115M FCF on a ~$11B market cap — a binary bet on NRC timelines.
BWXT is the soundest business (defense-anchored FCF) but the worst tape.
Fintech / stablecoins / crypto equities
What’s driving it. The 2025 stablecoin-legislation euphoria has fully reversed. CRCL is verified at $90.13 (-10.63%), -70% off its high and below both MAs.
COIN is at $163.22 (-6.19%), -63% off its high, below both MAs. IBIT and the crypto-miner complex are soft too — this is theme fatigue, not a one-name issue.
Durability. Broken. This is on the watchlist to track as it bottoms, not to chase.
There is no sign of a base yet. Do not catch this falling knife.
Leaders’ fundamental health. Mixed-to-poor and de-rating. Coinbase has a real business but earnings are volatile with crypto volumes; Circle's valuation imploded post-IPO.
The fundamental story is hostage to crypto prices and regulatory sentiment, both of which turned against the group.
Neocloud / AI Datacenter Buildout (GPU-rental + servers)
carried forward
What’s driving it. Vera Rubin NVL72 validation (CRWV, 06-01), HPE's record Q2 FY26 beat ($10.68B rev +40% YoY, biggest beat since 2018), and multi-year hyperscaler capacity contracts (NBIS Microsoft $17B + Meta $27B; CRWV $99.4B backlog; IREN Microsoft $9.7B + NVIDIA $3.4B).
Durability. Short-term momentum is real but fragile — three of four names carry Weak/Stretched balance sheets and the group is a laggard catching up to the extended parent (CRWV still ~33% below its $187 high). The contracts are multi-year, but the leverage (CRWV current ratio 0.31, working capital -$12.2B, Q1 FCF -$4.7B) means this is the highest tail-risk expression of the AI buildout; durability is contract-backed but financially precarious.
Leaders’ fundamental health. Weak-to-mixed in aggregate — the lowest-quality theme in the AI complex. CRWV is Weak (current ratio 0.31, WC -$12.2B, Q1 FCF -$4.7B, D/E 3.7x, EV/S ~27x).
NBIS is Stretched (EV/S ~68x, Q1 GAAP 'profit' is ~$743M non-operating other income masking a -$128M operating loss) but has the best balance sheet (current ratio 8.3x, near-net-cash). IREN is Weak (FCF -$0.92B/qtr, beta 4.18, revenue DECLINING sequentially $240M→$185M→$145M as the mining base winds down faster than AI ramps).
HPE is the only FCF-positive name (Mixed: EV/S ~5x, P/E ~16x, ~5.2% FCF yield) but thin AI-server margins.
Core watchlist — the fundamentally-strong names we track
The persistent core. Leaders scored 0–100 (deterministically, from a point-in-time fundamentals cache) on a CANSLIM + SEPA growth-leader quality fingerprint — durable revenue growth, earnings inflection, margin expansion, high ROIC, and free-cash-flow generation (O’Neil + Minervini + the quality-factor literature), plus a small-cap runway tilt. Winner-grade names (≥60) are carried forward run-to-run and tracked here. The RS leaders that fail the profile still appear on the theme cards as current momentum, but are NOT tracked (momentum is transient). Quality measures “a great, improving business now”; the runway term is the one factor earned by our own survivorship-corrected backtest (among RS leaders, smaller cap was the only strong forward signal — a fat upside tail), gated on cash support so it rewards small cash-generative growers, not cash-burning lottery tickets. A high score on a mega-cap is still a quality read (its runway is capped), not a forward-multibagger one. Descriptive, not a forecast.
Proven compounderswinner-grade · tracked core · mature / large-cap15
Emerging candidateswinner-grade · tracked core · small-enough base to still compound17
Momentum — not trackedRS leaders shown on the cards; fundamentals don't match the winner fingerprint (transient)29
Top actionable ideas
Entry. buyable-near-pivot
Thesis. The quality energy leader at a value price. EOG beats XLE on both YTD (+32% vs +29%) and 3-month (+10.5% vs +3.9%), trades above both moving averages, and carries the cleanest balance sheet in the group.
Unlike WMB (which verification kicked out as a laggard), EOG is a confirmed leader you are not overpaying for.
Risk. Crude is the swing factor — WTI base case ~$59 for 2026 on non-OPEC supply. EPS already slipped YoY ($11.31→$9.24) on softer prices.
If oil rolls, the cheap multiple gets cheaper. Energy as a theme is decelerating (extended-late), so this is a stock-specific quality call inside a tired theme.
Entry. constructive-basing
Thesis. The cleanest early-rotation entry in the entire set. Equal-weight biotech is turning from years of laggard status into leadership, and crucially it is NOT yet extended — it is bouncing off its 200-day while still below its 50-day and 7% under its 52-week high.
The equal-weight structure means you own breadth, not a single binary bet.
Risk. Early and unconfirmed — it is still below its 50-day, so the rotation is not yet proven. A rate-cut delay (the same firmer labor data hurting gold) would pressure small-cap funding.
Trigger to confirm: a decisive close above the 50-day ($131.43). Do not over-read the day's single-name pops (ABVX +24%) as the thesis.
Entry. buyable-near-pivot
Thesis. The best risk/reward in a high-conviction theme. PANW genuinely leads (beats CIBR on every window — +80% over 3 months vs +43%) but is the most reasonably valued of the cyber majors, with real FCF backing it.
Today's -5.6% post-print drop pulled it ~7% off its high — a buyable pivot rather than a chase. Contrast with FTNT, which is the cleanest fundamentally but sits within 1.7% of its high (extended).
Risk. The -5.6% print could see a failed bounce — watch whether it holds above the 50-day. The $25B CyberArk deal adds integration and dilution overhang, and platformization front-loads discounts that pressure near-term billings.
Still GAAP-profitable but the multiple needs growth to hold.
Entry. constructive-basing
Thesis. The quality way to own copper without chasing an extended leader. FCX is the strongest name but is pressing its 52-week high after a +27% month (extended-chasing).
SCCO is the YTD leader that is currently basing — 11% off its high — with by far the best asset base in the group. You buy a fortress balance sheet on a pullback rather than chasing FCX into strength.
Risk. Richest valuation in the basket (EV/EBITDA ~15x, P/B ~11x) leaves little cushion if copper pulls back. It lagged the COPX proxy over the trailing 3 months (-4.7% absolute), so near-term relative strength has faded.
Jurisdiction concentration in Peru/Mexico (permitting, royalty, community risk). Avoid TECK as the copper expression — its tape is strong but FCF is negative and ROIC under 3%.
Entry. constructive-basing
Thesis. The single genuinely-leading name inside a broken Healthcare sector. While XLV sits below its 200-day, Lilly re-accelerated and printed GREEN on a hard risk-off day — up 7.9% over 3 months while the sector fell 5.9%.
The new oral GLP-1 (Foundayo/orforglipron, FDA-approved 2026-04-01, Q2-2026 launch) is a fresh catalyst. Do not buy the Healthcare sector; buy this one name.
Risk. Valuation is the whole risk — EV/S ~15x and FCF yield under 1% leave zero room for a stumble. P/E 47x prices in continued hyper-growth.
Any GLP-1 competitive setback or guidance miss is an outsized drawdown. This is a narrow single-name bet, not diversified sector exposure.
Entry. constructive-basing
Thesis. The cleanest way to own the power second-derivative of AI. GE Vernova is the clear leader of the equipment sub-group (+46.8% YTD), consolidating constructively below its 50-day but well above a rising 200-day — digesting a run, not breaking.
The backlog is the tell: gas-turbine backlog grew 83→100 GW in Q1 2026 with $2.4B of data-center electrification orders. Own this over the speculative SMR names that cratered 11-12%.
Risk. Valuation is Stretched — EV/EBITDA ~46x trailing on a ~$258B cap. Multiple-compression risk is real if AI-capex expectations cool.
The backlog supports it, but you are paying a premium for the highest-quality name in the theme. The 19% drawdown from the high shows it is volatile.
Emerging / early-rotation watch
- Biotech rotation confirmation (XBI): the highest-quality early signal in the set. Trigger to add: a decisive close above the 50-day ($131.43), then a break of the 52-week high ($139.19).Driver is durable (rate cuts + ~$29B M&A wave + FDA approvals). The risk is a rate-cut delay choking small-cap funding.
- Selective medtech breakouts (EW, GKOS): a narrow, stock-specific early theme. Edwards is breaking out of a six-month base on ~+42% YoY heart-therapy growth; Glaukos is reclaiming its 200-day. Trigger: EW holding above its breakout and GKOS confirming above the 200-day. Watch-it-don't-chase because the broad device proxy IHI is the weakest in the RS setthere is no sector tailwind, so it lives or dies on 2-3 names.
- Memory/HBM second wave (LRCX, TER): if the DRAM shortage persists, the equipment names that supply memory fabs are the next leg. Trigger: MU holding its 52-week high while LRCX/TER break out of their bases. The whole sub-theme is hostage to one variableDRAM spot pricing — so a pricing roll-over is the kill switch.
- Custom silicon vs GPU (AVGO, MRVL): leadership is migrating from NVDA's merchant-GPU layer toward custom ASICs. MRVL printed +3.73% green the day NVDA fell 3.55%.Trigger: AVGO/MRVL sustaining relative strength vs NVDA through the next earnings cycle would confirm the down-stack rotation.
Avoid / fading
- WMB (Williams)verification kicked this OUT as an energy leader. It is negative on both 1-month (-5.0%) and 3-month (-5.5%) while XLE rose, YTD +18% trails XLE +29%, it is below its 50-day, and it is the most stretched name in the group (net-debt/EBITDA ~3.95x, P/E 28x, FCF yield 1.4%).The data-center-gas thesis is priced in while the tape has broken. The proposal called it a leader; the live data says laggard.
- Fintech / stablecoin / crypto equities (CRCL, COIN)the clearest fully-broken theme. CRCL -70% off its high (below both MAs), COIN -63% off its high (below both MAs), both led losers again today.The 2025 stablecoin euphoria has fully reversed. No base yet — track it bottoming, do not chase.
- Speculative nuclear / SMR fuel-cycle (OKLO, LEU, UEC, SMR)decoupled from the durable power trade and de-rating hard. OKLO -11.24% on the day and -66% off its high, pre-revenue and burning -$115M FCF on an ~$11B cap.BWXT, despite a sound business, is broken on the tape (below both MAs, -14.8% over the month). Own GEV/CEG for power, not these.
- Quantum pure-plays (QBTS, RGTI)fading on momentum and worse on fundamentals than the bull case admits. Verification found QBTS's growth story is FALSE: recognized revenue is FALLING ($15.0M → $2.86M over five quarters), the 'growth' is bookings optics.RGTI has a NEGATIVE gross margin and only ~$48M cash. Both IONQ's and RGTI's 'GAAP profits' are non-operating warrant gains.The Quantinuum IPO is siphoning capital. If you must own quantum, IBM is the only cash-generative expression — but it barely tracks the theme.
- Gold & precious metals (GDX, SLV)extended and correcting, not leading. GDX is below both MAs and -27.5% off its high (deepest drawdown in the set); silver is ~40% off its high.The metals bid narrowed into copper and oil. Wait for a base.
- Chasing extended leaders at fresh highs (FCX, FTNT)both are genuine leaders but sit within ~2% of their 52-week highs after large one-month moves. Strong businesses, poor entries.Prefer the basing names in the same themes (SCCO for copper, PANW for cyber).
Caveats
- Descriptive, not a forecast. Every status, leader call and fundamental rating describes what the live tape and financials show as of the 2026-06-03 close. None of it predicts forward returns. Trends labeled 'extended-late' or 'established-leading' have already moved — the labels flag where the easy money likely is behind us, not where it is going.
- Data-as-of 2026-06-03 close. Prices, returns and moving averages are point-in-time. Several leaders are within a few percent of 52-week highs or sitting on key moving averages, so the entry-context calls (buyable / basing / extended) can flip within days. Re-check live quotes before acting.
- Rotation-reversal risk is the dominant hazard here. The whole readout rests on a late-stage, extended AI/tech bull. Semis sit 63% above their 200-day at the 99th percentile of their range. A genuine AI-capex pause would hit semis, memory, cooling, power and copper TOGETHER — these are not independent themes, they are layers of one trade.
- Correlation hazard / false diversification. The top ideas (semis, memory, cooling, power, copper, even parts of cyber) are all expressions of the same AI-capex thesis. Holding six of them is not diversification — it is one concentrated bet with six tickers. Size accordingly and treat the AI-capex layers as a single risk factor.
- Verification corrected several theses, and those corrections matter: WMB is a laggard not a leader; TLN's fundamental health is Weak (FY2025 GAAP loss, ~14.6x net leverage) not Strong; QBTS's growth story is false (revenue falling, not rising); BWXT is broken on the tape not a pick-and-shovel leader; TECK leads on price but has negative FCF; IONQ/RGTI 'GAAP profits' are warrant gains, not earnings. Where the original narrative and the measured price disagreed, the price won.
- Remaining uncertainty I am NOT smoothing over: (1) The memory/HBM and copper theses hinge on commodity pricing (DRAM, copper) that can roll over fast and is not independently forecast here. (2) The biotech rotation is unconfirmed — XBI is still below its 50-day. (3) Energy equity strength has decoupled from a bearish crude base case (~$59 WTI), so the dividend/buyback bid could break. (4) Not every theme was re-verified at the single-name level — Semiconductors, Memory, Cooling, Cybersecurity-proxy and the spec themes draw partly on the proposal's own live reads rather than fully independent re-pulls.
- Not personalized investment advice. This is a research readout for a sophisticated investor's own judgment. No position sizing, suitability, tax or risk-tolerance assessment has been applied. Falsifiable numbers are included precisely so each idea can be checked and discarded if the data moves against it.
What’s driving it. The AI capex super-cycle. The narrative tried to call Tech the rotation-out source on one red session, but measured price refutes it: SMH +77% YTD, at a fresh 52-week high ($642.77), and 63% above its 200-day ($391.94).
Leadership is broadening down-stack — INTC, MRVL and NVTS printed green the same day NVDA fell 3.55%.
Durability. Sustainable as a multi-year capex theme, but the LEVEL is the risk. At the 99th percentile of its range and 63% above the 200-day, this is extended.
A one-day flush is exactly what late-stage leaders do. Buy pullbacks, do not chase fresh highs.
Leaders’ fundamental health. Strong in aggregate. These are high-gross-margin, FCF-rich franchises (AVGO, NVDA, TSM) with net-cash or modest leverage.
The shared caveat is valuation: multiples already discount sustained AI capex, so any spending pause re-rates the whole group.